This study is looking into the EGFR gene, which is often changed in non-small cell lung cancer. Researchers have a new way to estimate the risk of getting a cancer-related gene change. They will collect blood samples from people with EGFR-positive lung cancer and healthy individuals. They will then look at the DNA sequence around the EGFR gene using a method called gene sequencing. The goal is to use these samples to check if their risk assessment model works, which could eventually help understand who might be more likely to get EGFR-positive lung cancer or other cancers. This study is open to women between 18 and 100 years old.

Study design

This is an observational study aiming to enroll 20 participants. It compares DNA sequences from individuals with EGFR-positive lung cancer to healthy individuals.

What's involved

You would have a 10ml blood sample taken for gene sequencing. The primary endpoint, which is looking at differences in DNA sequences, will be measured from enrollment to the end of data analysis at 6 months.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured from enrollment to the end of data analysis at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.